Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Surface bound protein subunits
What ifWhat if individual apoferritin subunits are tethered to solid beads and toxin binding occurs at the bead surface?
Claim language“form an internal void when assembled”
A dissociated apoferritin preparation is coupled at low surface density to activated polymer beads, which immobilize the subunits as separate molecules. Quaternary ammonium groups on the same bead surface capture dissolved anionic toxins as dialysate flows through the bed.
1.1Iron oxide filled cage
What ifWhat if the protein cage encloses an iron oxide nanoparticle during toxin capture?
Claim language“does not contain any nanoparticles in its internal void”
Ferrous ions enter the assembled protein shell through its channels and oxidize to form an iron oxide nanocore. The mineral-loaded cages are immobilized on porous resin beads, where external protein surfaces remain accessible to dissolved toxins.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Copper uptake testing in rinse water
A bench column holds apoferritin cages immobilized on porous agarose beads for testing rinse water from metal finishing. The cages consist of assembled apoferritin subunits and contain no nanoparticles in their cavities. A metering pump feeds filtered rinse water through the bed, and a colorimetric assay measures dissolved copper in paired inlet and outlet samples. A second column packed with the same agarose without apoferritin measures copper uptake by the support.
Component substitution
Activated carbon replaces the protein cages
A cartridge packed with medical-grade granular activated carbon replaces the apoferritin sorbent on the dialysate side of a hemodialysis circuit. Porous retaining screens hold the granules inside the housing, and a downstream particle filter captures carbon fines. Dialysate leaving the dialyzer flows through the bed, where dissolved organic solutes such as creatinine adsorb onto the carbon.
Parameter or scale variation
Bench columns with varied contact times
Three columns each hold 10 mL of porous agarose beads carrying immobilized apoferritin cages with no nanoparticles in their cavities. Separate pumps feed the same model dialysate through the columns at 1, 2 and 5 mL/min, giving nominal empty-bed contact times of 10, 5 and 2 minutes. Outlet samples collected after every five bed volumes provide breakthrough curves for each flow rate.
Series cartridges with interstage sampling
Two cartridges each contain 25 mL of beads carrying immobilized apoferritin cages with no nanoparticles in their cavities. Tubing connects the cartridges in series, and a pump feeds model dialysate through both at 5 mL/min. Sampling ports at the inlet, between the cartridges and at the final outlet track solute breakthrough in each bed. When the interstage concentration reaches the selected threshold, the operator moves the downstream cartridge into the lead position and installs a fresh downstream cartridge.
Combination with existing systems
Apoferritin bed in a regeneration loop
A recirculating dialysate system places a cartridge of immobilized apoferritin cages downstream of the dialyzer and upstream of a urease and ion-exchange stage. The apoferritin cavities contain no nanoparticles, and the cartridge contacts spent dialysate as it leaves the dialyzer. Urease converts urea to ammonium and bicarbonate, and the ion-exchange bed captures ammonium. Conductivity and pH sensors guide concentrate dosing in a mixing reservoir before the pump returns dialysate to the dialyzer.
Automated or data-driven variant
Automatic cartridge exchange at measured breakthrough
Two parallel cartridges hold immobilized apoferritin cages with no nanoparticles in their cavities, and motorized valves direct model dialysate through one cartridge at a time. An automated sampler feeds paired inlet and outlet samples to a liquid chromatograph that measures a selected solute. When the outlet concentration reaches 10 percent of the inlet concentration in two consecutive sample pairs, a controller switches flow to the standby cartridge and records the processed volume.
Specific version of a part
Recombinant heavy chain cage
Recombinant ferritin heavy-chain subunits self-assemble into a 24-subunit shell with an internal cavity. Preparation in iron-depleted buffer leaves the cavity filled with aqueous buffer and free of particulate material.
Demineralized light chain cage
A reducing agent converts the ferric mineral in a light-chain ferritin cage to soluble ferrous ions, and a chelator captures the released iron in solution. Buffer exchange removes the soluble iron complex, leaving the assembled shell with a particle-free internal cavity.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1the apoferritin nanoparticle comprises apoferritin subunits which form an internal void when assembled into the apoferritin nanoparticle, and wherein the apoferritin nanoparticle does not contain any nanoparticles in its internal void.
The ferritin has, in vivo, a core 1 of iron oxide with a diameter of 7 nm at most within a shell 2 of the protein. Ferritin from which the iron oxide core 1 has been slipped off is designated as apoferritin.
A · US 7,897,408 B2 · ¶ 3
Characteristic for the nanoparticle is that the shell of the nanoparticle is a recombinant apoferritin or an apoferritin-like particle.
B · US 2011/0300558 A1 · ¶ 16
An empty cell means only that no passage was reproduced there.
Statements in these documents
A semiconductor nanoparticle with high crystallinity is necessary as a material of a semiconductor device but a nanoparticle made of a compound semiconductor and capable of emitting light cannot be produced by employing the bio-nanoprocess.
A · US 7,897,408 B2 · ¶ 7
An object of the invention is producing a nanoparticle made of a compound semiconductor and capable of emitting light.
A · US 7,897,408 B2 · ¶ 8
More specifically this invention relates to ferritin particles for bioaffinity assays.
B · US 2011/0300558 A1 · ¶ 1
They can infect their hosts by accident and accordingly result in uncontrolled outbreak of viruses or phages.
B · US 2011/0300558 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355715 A1, claim 1, first published 2026-11-19T14:30:38-05:00, https://patent.fyi/US20260355715/, SHA-256 e8728fa5cbabfc0dabfac5e20f854c1bcad0a1aecdb3628f4201e74fb221ab29